Evidensgrunnlag for forsvarlig seponering av antipsykotika
Evidensgrunnlag: Evidensgrunnlaget er basert på en Cochrane oversiktsartikkel (Declercq et al., 2013). Den omfatter ni studier med totalt 606 pasienter med demens, hvorav sju studier av sykehjemspasienter, én studie på hjemmeboende og én på et blandet utvalg pasienter (sykehjem/hjemmeboende). Pasientene hadde brukt antipsykotika fra 4 uker til 6 måneder før seponering. Type av antipsykotika som ble seponert og dosering før seponering, varierte i studiene.
Evidenskvalitet: Evidenskvaliteten på de inkluderte studiene er vurdert som god med hensyn til risiko for systematiske feil, men utvalgene er for små i de fleste studiene til å kunne oppdage klinisk meningsfulle forskjeller mellom gruppene på effektmål. Et annet problem er at de inkluderte studiene anvendte ulike effektmål og rapporterte resultater ulikt (numerisk/deskriptivt). Det bidro til at det ikke er utført meta-analyser. Det er ikke gjort GRADE-kvalitetsvurdering.
Tidsperiode: Seponering ble gjennomført brått i tre studier, gradvis i fire studier eller brått eller gradvis avhengig av dose i to studier.
Effekter: Resultatene viser at i 4 av 6 studier var det ingen statistisk signifikant forskjell mellom seponeringsgruppe og behandlingsgruppe i antall pasienter som falt fra i studieperioden på grunn av forverring av symptomer. I de to studiene som fant høyere frafall på grunn av symptomforverring i seponeringsgruppen, omfattet disse pasienter med markerte psykotiske symptomer og/eller agitasjon, med total NPI-skår>14 som tidligere hadde respondert godt på den antipsykotiske behandlingen, enten med haloperidol eller risperidon. Seks (av ni) studier målte endring i APSD-symptomer over studieperioden og ingen av dem fant statistisk signifikant forverring i seponeringsgruppen sammenlignet med gruppen som kontinuerte den antipsykotiske behandlingen. Seks (av ni) studier målte endring i kognitiv funksjon uten at det ble funnet statistisk signifikante forskjeller mellom gruppene.
Bivirkninger: Fem (av ni) studier målte bivirkninger. Det ble ikke funnet statistisk signifikante forskjeller mellom seponerings- og behandlingsgruppene. Ingen av de inkluderte studiene målte symptomer på abstinens under seponering.
Konklusjon: Forfatterne konkluderer med at de fleste eldre personer med demens og APSD som har brukt antipsykotika over tid, kan seponere legemidlene uten forverring av symptomer. Det er imidlertid mulig at pasienter med alvorlige symptomer på APSD (total NPI-skår>14) som har respondert godt på behandlingen, kan ha nytte av fortsatt å bruke antipsykotika over tid.
Referanser
Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet (London, England) 1998;351(9108):1032-3
Banerjee S.: The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services, NHS, England, 2009
Birks J: Cholinesterase inhibitors for Alzheimer's disease. The Cochrane database of systematic reviews 2006;(1):CD005593
Boxer AL, Boeve BF: Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer disease and associated disorders 2007; 21(4): S79-87
Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Pollock BG: Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer disease and associated disorders. 2010;24(4):360-4.
Cummings JL, Street J, Masterman D, Clark WS: Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dementia and geriatric cognitive disorders 2002;13(2):67-73
Curtis RC, Resch DS: Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. Journal of clinical psychopharmacology 2000;20(3):384-5
Czarnecki K, Kumar N, Josephs KA: Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics? European journal of neurology 2008;15(2):199-201
Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AIM, van Driel ML, Christiaens T: Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. The Cochrane database of systematic reviews 2013;(3): CD007726
Fellgiebel A, Müller MJ, Hiemke C, Bartenstein P, Schreckenberger M: Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry 2007;8(2):123-6
Hulshof TA, Zuidema SU, Ostelo RWJG, Luijendijk HJ: The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Journal of the American Medical Directors Association 2015;16(10):817-24
Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S: Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population-based cohort study. BMJ (Clinical research ed.) 2012;344 e977
Kerssens CJ, Kerrsens CJ, Pijnenburg YAL: Vulnerability to neuroleptic side effects in frontotemporal dementia. European journal of neurology 2008;15(2):111-2
Kurlan R, Cummings J, Raman R, Thal L: Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68(17):1356-63
Lee HB, Hanner JA, Yokley JL, Appleby B, Hurowitz L, Lyketsos CG: Clozapine for treatment-resistant agitation in dementia. Journal of geriatric psychiatry and neurology 2007;20(3):178-82
Lockhart IA, Orme ME, Mitchell SA: The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. Dementia and geriatric cognitive disorders extra 2011;1(1):212-27
Lonergan E, Luxenberg J, Colford J: Haloperidol for agitation in dementia. The Cochrane database of systematic reviews 2002;(2):CD002852
Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA, Motala A, Perry T: Off-Label Use of Atypical Antipsychotics: An Update, Comparative Effectiveness Review No. 43. 2011
Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. Report No.: 11-EHC087-EF.
Maher AR, Theodore G: Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. Journal of managed care pharmacy: JMCP 2012;18(5 Suppl B): S1-20
Matsunaga S, Kishi T, Iwata N: Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PloS one 2015;10(4):e0123289
Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC : Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.. JAMA psychiatry 2015;72(5):438-45
Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A: Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. American journal of Alzheimer's disease and other dementias. 2003; 18(4):205-14
McKeith I, Fairbairn A, Perry R, Thompson P, Perry E: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ (Clinical research ed.) 1992;305(6855):673-8
Off-Label Use of Atypical Antipsychotics: An Update, Comparative Effectiveness Review No. 43. Report prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I for the Agency for Healthcare Research and Quality, 2011
Pijnenburg YAL, Sampson EL, Harvey RJ, Fox NC, Rossor MN: Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. International journal of geriatric psychiatry 2003;18(1):67-72
Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM: The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. Journal of neurology 2006;253(2):171-5
Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS, Wills CD, Rhoads R, Yager J: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. The American journal of psychiatry 2016;173(5):543-6
Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, Wilson K, Le Clair K, Conn DK: Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. International psychogeriatrics / IPA 2013;25(2):185-203
Tan L, Tan L, Wang H-F, Wang J, Tan C-C, Tan M-S, Meng X-F, Wang C, Yu J-T: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer's research & therapy 2015;7(1):20
Sink KM, Holden KF, Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293(5):596-608
Stinton C, McKeith I, Taylor J-P, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT: Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. The American journal of psychiatry 2015;172(8):731-42
Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T: Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Progress in neuro-psychopharmacology & biological psychiatry 2003;27(3):549-53
Tan L, Tan L, Wang H-F et al: Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimer's research & therapy 2015;7(1):20
Trinh N-H, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289(2):210-6
Wang J, Yu J-T, Wang H-F, Meng X-F, Wang C, Tan C-C, Tan L: Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. Journal of neurology, neurosurgery, and psychiatry 2015;86(1):101-9
Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, McKeith IG: Olanzapine in dementia with Lewy bodies: a clinical study. International journal of geriatric psychiatry 1999;14(6):459-66
Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, Burn D, Ballard CG: Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. The Journal of clinical psychiatry 2005;66(5):633-7